Detail Study on COVID-19 Diagnostics Market is Projected to Grow Magnificent CAGR till 2027

 Market Highlights

Global COVID-19 Diagnostics Market report is expected to register a CAGR of 6.28% during the forecast period, with a market value of USD 96,293.9 Million by 2027. COVID-19 is one of the most harmful infectious diseases that is caused by a coronavirus. Wuhan, China was the first place to experience the disease’s outbreak, followed by Europe, and then to the other countries globally by infected people.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/9710 

Segment Analysis

Global COVID-19 Diagnostics Market has been segmented by Type, Technology, and End Users. The market, based on type, has been bifurcated into molecular tests and serology tests. On the basis of technology, the market has been bifurcated into RT-PCR, isothermal amplification, CRISPR, ELISA, hybridization, and others.

Based on End User, the COVID-19 diagnostics market has been segregated into hospitals, public health labs, private or commercial labs, and others.

Regional Analysis

Global COVID-19 Diagnostics Market, based on region, has been divided into the Europe, Americas, Asia-Pacific, and the Middle East & Africa.

The Europe is likely to dominate the global COVID-19 diagnostics market. This can be attributed to the high COVID-19 morbidity and mortality observed among residents in long-term care facilities (LTCF) in European Union (EU) and European Economic Area (EEA) pose a major challenge for disease prevention and control in such settings, which raises the demand for the wide availability of diagnostics for immediate detection of COVID-19 cases. According to European Centre for Disease Control and Prevention, 157 312 deaths in the EU/EEA and the UK as of 19 May 2020 were reported. Moreover, the support from public & private organizations in tackling COVID-19 is also expected to drive market growth in the region.

The American market for COVID-19 diagnostics is expected to be the second largest during the forecast period. Rising product launches by major players and ongoing public and private organizations’ efforts to control the spread of the virus is anticipated to drive the market growth. For instance, in March 2020, the US FDA issued a EUA for a molecular point of care test kit by Abbott for the rapid detection of COVID-19. Furthermore, the increasing numbers of corona virus-positive cases also act as a driving factor and support market growth.

Asia-Pacific is estimated to be the fastest-growing market. With an increasing number of cases, governments across the Asia-Pacific countries are exploring the opportunities of allowing private laboratories to ramp up testing, which is boosting the market growth. For instance, In India, the Indian Council of Medical Research (ICMR) has approved 51 private laboratories for COVID-19 testing on March 31, 2020. Moreover, the increasing number of COVID-19 cases is also driving the market growth.

The market in the Middle East & Africa is expected to witness steady growth. Countries such as Kuwait, the UAE, and Saudi Arabia are likely to show steady growth due to increasing COVID-19 cases and rising initiatives by governments to improve patient care.Key Players

MRFR recognizes the following companies as the Key Players in the Global COVID-19 Diagnostics Market— Becton, Dickinson & Company (US), Bio-Rad Laboratories (US), Danaher Corporation (US), Abbott (US), F. Hoffmann-La Roche Ltd (Switzerland), Biomerieux SA (France), Genmark Diagnostics (US), Thermo Fisher Scientific (US), Qiagen (Germany), and Siemens AG (Germany).

Key Findings of the Study

• Global COVID-19 Diagnostics Market is estimated to reach USD 96,293.86 million by 2027 at a CAGR of 6.28% during the assessment period
• The Europe accounted for the largest share of the global COVID-19 diagnostics market due to the increasing number of COVID-19 cases
• Based on type, the molecular tests segment accounted for the largest market share of 58.3% in 2020
• On the basis of technology, the RT-PCR segment accounted for the largest market share of 25.4% in 2020
• On the basis of end user, the hospitals segment accounted for the largest market share of 33.6% in 2020

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/covid-19-diagnostics-market-9710

Future Growth of Genotyping Market is Expected to Grow Healthy CAGR till 2023

 Market Highlights

Genotyping is a procedure commonly used in healthcare and life sciences research activities. Genotyping is a genetic mapping of an organism which includes DNA sequencing and analysis of sequenced DNA. The surge in cases of genetic disorders, increasing demand for personalized medicines, and technological advancement are the factors that are propelling the growth of the market. Additionally, increasing R&D spending and aggressive strategies adopted by the top players, such as new product launches, are contributing to the growth of the market. For instance, in January 2018, Illumina, Inc. launched iSeq 100 Sequencing System in the market, the product contains sequencing by synthesis (SBS) along with the complementary metal-oxide-semiconductor (CMOS) detection technology which is easy to use and compact product.  

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6635 

The unfavorable reimbursement policies, the dearth of technicians, and continues change in technology are likely to hinder market growth during the forecast period.

Regional Analysis

The market in the Americas is expected to dominate the global genotyping assay market during the forecast period owing to the rising demand for personalized medicines, growing research and development sector, increasing cases of genetic disorders, and well-established healthcare sector in the region. The European market is expected to be the second-largest due to government funding and support of the healthcare sector, rising investment into research and development by pharmaceutical companies, and increasing government initiatives for development of healthcare sector. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to the increasing disposable income, supportive government policies, and rising investment by market players in the region. The market in the Middle East & Africa is likely to account for the smallest share of the global genotyping market.

Segmentation

The Global Genotyping Market has been segmented on the basis of technology, product, application, and end-user.

The technology segment has been segregated into sequencing, capillary electrophoresis, PCR, microarray, and mass spectrometry. The sequencing segment has been further divided into next-generation sequencing, pyrosequencing, and Sanger sequencing. The Capillary electrophoresis segment has been further divided into amplified fragment length polymorphism (AFLP),single-strand conformation polymorphism (SSCP), and restriction fragment length polymorphism (RFLP). The microarray segment has been classified as DNA microarrays, antibody microarrays, MMChips, and peptide microarrays.

On the basis of product, the market has been divided into reagents and kits, instruments, and services.

 The market, by application, has been classified into diagnostics, drug discovery and development, agriculture, academic research, and personalized medicine.

The end-user segment has been classified into hospitals, diagnostic centers, academic institutes, and research and development centers.

Key Players

Some of the key players in the global genotyping market are F. Hoffmann-La Roche Ltd, QIAGEN, Thermo Fisher Scientific, Inc., Illumina, Inc, Fluidigm Corporation, General Electric Company, Affymetrix, Inc., Agilent Technologies, Inc., Sequenom, and Beckman Coulter, Inc.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/genotyping-market-6635

Cell Surface Markers Market is Growing Massively till 2023

 

Market Highlights

The global cell surface markers industry is anticipated to hold a market value of USD 498 million in the year 2017 and is expected to grow at a CAGR of 8.4% during the forecast period. Cell surface markers or cell surface antigen work as monograms for identification and classification of cells. The proteins that are expressed on the cell surfaces often conveniently work as markers for specific types of cells.

Increasing expenditure in the advancement of healthcare technology, advancement in technology, acquisitions by companies and outlook for reduction of costs associated with disease diagnosis are expected to drive the growth in the market over the forecast period. For instance, in April 2014, Beckman Coulter, acquired Xitogen Technologies, a cytometer manufacturer. This acquisition helped Beckman Coulter to broaden its product offerings and enabled business expansion in Asia.  However, complex products and expensive instruments & reagents can restrain the market growth over the assessment period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7410 

Regional Analysis

Geographically, the Americas is expected to dominate the global market owing to the significant amount of research and development activities and well-developed healthcare infrastructure. According to the Organization for Economic Co-operation and Development(OECD), In 2016 united states has spent USD 464,324 million on research and development activities which is 2.7% of total GDP.  Europe is expected to hold the second largest position in the global market owing to the well-developed healthcare infrastructure. Asia-Pacific is expected to be the fastest growing market owing to the growing demand for user friendly targeted therapies. Moreover, the Middle East and Africa region is expected to account for the least market share in the global market.

Segmentation

The global cell surface markers market has been segmented into product, source, cell type and application.

The market, on the basis of product, has been segmented into antibody and PCR array.

The global market, on the basis of source, has been segmented into mice, rat and others.

The global market, on the basis of cell type, has been segmented into T cells, B cells and NK cells. T cells are expected to hold the largest market share owing to high usage of them in research and diagnostics. NK cells are expected to grow at the fastest CAGR owing to increasing application of these types of cell.

The global cell surface markers market, by application, has been segmented into research, clinical and others. Research segment has been further divided into stem cell and immunology. Clinical segment is further divided into oncology and hematology.

Key Players

Some of the prominent players in the global cell surface markers market are Bio-Rad Laboratories, Inc., Abbott, Siemens Healthcare Private Limited, Beckman Coulter, Inc. , F. Hoffmann-La Roche Ltd, NIHON KOHDEN CORPORATION, Thermo Fisher Scientific, BD, Abcam plc., QIAGEN, Danaher, GenScript, Merk KGaA, BioLegend, Inc., Cell Signaling Technology, Inc., Bio-Techne and Others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/cell-surface-markers-market-7410 

Preclinical Imaging Market | Worldwide Top key Players Profile Analysis | Forecast till 2023

 

Market Highlights

The global preclinical imaging market size anticipated to have held a market value of USD 2.01 billion in the year 2017 and is expected to grow at a CAGR of 6.3% during the forecast period. Preclinical imaging solutions are used during the preclinical research for visualization of living animals. It is playing important role during drug development process. It is evaluating the effectiveness and safety of new treatments and describing drug distribution patterns before clinical use. preclinical imaging solutions has broad application field such as, neurology; cardiology; inflammation; infectious diseases; cancer research; functional and anatomical neuroimaging, orthopedics; and cardiac imaging.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7365  

Technological advancements in the field of molecular imaging, increasing market demand for non-invasive small-animal imaging techniques, and increasing funding to support preclinical researches are expected to drive the growth of preclinical imaging market. Many organization and foundation provide the funding support for the preclinical researche activity. The Alzheimer’s Drug Discovery Foundation was providing the funding opportunity for preclinical study up to USD 5 million. Similarly, in 2015 Deutsches Zentrum für Herz-Kreislaufforschung e.V. (DZHK) offered Euro 6 million for the preclinical research projects. This funding supports the market growth.

Regional Analysis

Geographically, the Americas is expected to dominate the global preclinical imaging market owing to the presence of well-established players, technological advancements in the field of molecular imaging, increasing market demand for non-invasive small-animal imaging techniques, and increasing funding to support preclinical researches. Europe is expected to hold the second largest position in the global preclinical imaging market. Asia-Pacific is expected to be the fastest growing market owing to the increasing funding to support preclinical researches. Furthermore, the Middle East and Africa region is expected to account for the least market share in the global preclinical imaging market.

Segmentation

The global preclinical imaging market has been segmented into modality, reagent, and region.

Based on modality, preclinical imaging market is segmented into optical imaging systems, nuclear imaging systems, micro-MRI, micro-ultrasound, micro-CT, photoacoustic imaging system, and magnetic particle imaging systems. The optical imaging systems segment is expected to account for the largest share segment of the market in 2017.

Based on reagent, preclinical imaging market is segmented into preclinical optical imaging reagents, preclinical nuclear imaging reagents, preclinical MRI contrast agents, preclinical ultrasound contrast agents, and preclinical CT contrast agents. The preclinical optical imaging reagents segment is expected to account for the largest share segment of the market in 2017.

Key Players

Some of the prominent players in the global preclinical imaging market are Bruker Corporation (US), MR Solutions (UK), PerkinElmer Inc. (US), Fujifilm Holdings Corporation (Japan), Milabs B.V. (The Netherlands), Mediso Ltd. (Hungary), LI-COR, Inc. (US), Miltenyi Biotec GmbH (Germany), Aspect Imaging (Israel), and Trifoil Imaging (US).

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/preclinical-imaging-market-7365  

Future Growth of Veterinary Laboratory Testing Market is Expected to Grow Healthy CAGR till 2023

 

Market Highlights

The global veterinary laboratory testing market is expected to grow at a CAGR of 10.1% during the forecast period.

Increasing expenditure on pet insurance, growth in the number of veterinary practitioners, advancements in healthcare facilities, and favorable funding policies are expected to drive the market growth over the forecast period.

However, high cost of veterinary testing and complications associated with the tests can restrain the market growth over the assessment period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7326 

Regional Analysis

Geographically, the Americas is anticipated to dominate the global veterinary laboratory testing market owing to the increasing cases of animal disease and technological advancements in veterinary diagnostics. For instance, in 2016, IDEXX Laboratories, Inc. launched the Rapid Visual Pregnancy Test for cattle. With the new test, veterinarians can more quickly identify open cows using whole blood samples collected before the farm visit. Europe is expected to hold the second largest position in the global veterinary laboratory testing market. The market growth in this region is attributed to the rising expenditure on pet insurance. The Veterinary Laboratory Testing Market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the awareness regarding use of sterile consumables for lab testing and rising healthcare spending. The Middle East & Africa contributes least in the global market for veterinary laboratory testing.

Key Players

Some of the global veterinary laboratory testing market companies are Abaxis, Inc., BIOCHECK Inc., Biomérieux SA, Henry Schein, Inc., Heska Corporation, Idexx Laboratories, Idvet, Neogen Corporation, Pfizer, Qiagen N.V., Randox Laboratories, Ltd., Thermo Fisher Scientific, VCA Inc., Virbac, Zoetis, Inc. and others.

Segmentation

The global veterinary laboratory testing market has been segmented into animal type, technology, product, and end user.

The market, on the basis of animal type, has been segmented into companion animal and livestock animal. The companion animal segment is further classified as dogs, cats, horses and others. The livestock animal segment is further classified as cattle, pigs, poultry and others.

The market, by technology, has been segmented into clinical biochemistry, immunodiagnostics, hematology, molecular diagnostics, urinalysis, and others.

The clinical biochemistry segment is further classified as clinical chemistry analysis, glucose monitoring, and blood gas & electrolyte analysis. The clinical chemistry analysis segment includes clinical chemistry reagent clips and cartridges and clinical chemistry analyzers. The glucose monitoring segment includes blood glucose strips, glucose monitors and urine glucose strips. The blood gas & electrolyte analysis segment includes blood gas and electrolyte reagent clips and cartridges and blood gas & electrolyte analyzers.

The immunodiagnostics segment is further classified as ELISA tests, lateral flow assays, allergen-specific immunodiagnostic tests, immunoassay analyzers, and others. The lateral flow assays segment includes lateral flow rapid tests, and lateral flow strip readers.

The hematology segment is further classified as hematology cartridges, and hematology analyzers.

The molecular diagnostics segment is further classified as polymerase chain reaction (PCR) tests, microarrays, and others.

The urinalysis segment is further classified as urinalysis clips & cartridges/panels, urine analyzers, and urine test strips.

The market, by product, has been segmented into consumables and instruments.

The market, by end user, has been segmented into veterinary hospitals & clinics, in-house testing, research institutes, diagnostic laboratories, and others. The veterinary hospitals & clinics segment held the largest segment of the market in 2017. This can be attributed to the increasing incidence of zoonotic diseases. On the other hand, the academic institutes segment is estimated to be the fastest growing segment.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/veterinary-laboratory-testing-market-7326 

Single-Photon Emission Computed Tomography Market Projected to Witness Vigorous Expansion by 2023

 

Market Highlights

The growing acceptance of Single-Photon Emission Computed Tomography (SPECT) accustomed by its technical advances is one of the major trends witnessed in the global SPECT market over the forecast period. Imaging devices are becoming more advanced, efficient, and evolved in terms of technology. The SPECT scanner has two integral parts namely computed tomography (CT) and a radioactive material (tracer). Basically, these tracers are used to diagnose and predict outcomes in various disease states by monitoring the therapeutic effects.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1339 

The SPECT market is expected to witness tremendous growth owing to the new 99mtc labelled agents for visualizing biologically significant events, and integration of X-ray tomography (CT) In SPECT. Other key factors such significant investments in R&D and expansions undertaken by key players are contributing towards the growth of the market. However, challenges such as need for skilled professionals, and reimbursement issues, is likely to curb the market growth during the forecast period.

Segmentation

The global Single-Photon Emission Computed Tomography (SPECT) market is segmented into type, application, end-users. The Single-Photon Emission Computed Tomography (SPECT) market, by type, the market is segmented into hybrid SPECT systems, and standalone SPECT systems. On the basis of application, the Single-Photon Emission Computed Tomography (SPECT) market is bifurcated into oncology, cardiology, neurology, and others. On the basis of end-user, the market is segmented into hospitals, diagnostic imaging centers, academic & research centers, and others.

Regional Analysis

The Americas is the largest in the market owing to the improving research infrastructure in the region, coupled with the rising awareness among patients and physicians for radioisotopes. Further, SPECT has reportedly been combined with CT and MRI to provide detailed anatomical and metabolic information. It is currently exhibiting a highly lucrative growth rate due to an increased use of SPECT for diagnosis of cardiac diseases, brain diseases, etc.

The European region is the second largest SPECT market over the forecast period due to high acceptance of SPECT in research & development along with the rising incidence of chronic disease like cancers are also accountable for the growth of the Single-Photon Emission Computed Tomography (SPECT) market. 

The Asia Pacific region is likely to develop at the uppermost CAGR for the Single-Photon Emission Computed Tomography (SPECT) market in the years to come. Moreover, the rising diagnostic care services both at the hospitals and at community level are expected to influence the market in a positive way. The Middle East and Africa accounts for the least market share due to low per capita income and lack of availability of well-trained healthcare professionals.

Key Players

Some of the key players in the global Single-Photon Emission Computed Tomography (SPECT) market are GE Healthcare, Siemens Healthcare, Koninklijke Philips N.V., Bruker Corporation, Mediso Ltd., Digirad Corporation, Spectrum Dynamics Medical, DDD-Diagnostic A/S, MiE America, Inc., CardiArc, Beijing Hamamatsu Photon Techniques INC., SHENZHEN BASDA MEDICAL APPARATUS CO., LTD.

PNPMedM, NuCare Inc., and others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/single-photon-emission-computed-tomography-market-7231

Global Biologics Market Expected to Grow with a healthy CAGR

 Market Highlights

Global biologics market growth is expected to drive at a CAGR of 8.6% during forecasted period 2017-2023 and reach till $425 million by end of 2023. Biologics are the drugs prepare or obtain from the biological organism. They are composed of protein, sugars or nucleic acids.  This drugs are basically used in treatment of cancer and diabetes. Increasing prevalence of these diseases across the globe is the major responsible factor for the growth of the market. Beside this increasing demand for the better treatment, rising regulatory convergence and better access to healthcare for all nations has provided fuel for the growth of the market. On the other hand, biologic drugs are highly complex in nature and they must be controlled under maintained condition. This type of atmosphere and quality control is very difficult and requires a huge capital. This may hamper the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1339 

On regional basis, global biologic market is segmented as North America, Europe, Asia Pacific and Middle East and Africa. Almost 9% of total North America population is suffering from diabetes.  North America shares nearly half of the global biologic market due to increasing diabetic and cancer population, increasing healthcare expenditure and governmental support for the research and development. North America is followed by Europe. UK and Germany are the major contributor for the biologic market. Asia Pacific is the fastest growing region for the biologic market due to rapid development of health care sector and presence of rapidly growing economies like India and China. While Middle East and Africa has the least biologic market.

Segmentation:

Global biologic market is segmented on the basis of type into vaccines, blood products, proteins, gene therapy, and other. On the basis of application they are segmented into anemia, cancer, diabetes, and other. On the basis of source they are segmented as human, animal, microorganism, and other.

Some of the major players in the global neuromodulation market include Unilife Corporation (US), Sanofi (France), Retractable Technologies Inc. (US), Smiths Medicals (UK), Becton, Dickinson & Company (Germany), Terumo Corporation (Japan), Pfizer Inc. (US), Roche Diagnostics (Switzerland), Amgen (US), GSK Biologicals (UK), Lundbeck (Denmark), Novartis AG (Switzerland), AstraZeneca (UK), Bayer AG (Germany), Genzyme (US), Merck KGaA (Germany), Samsung Biologics (South Korea), Celltrion (South Korea), Addgene (US), Johnson & Johnson Inc. (US), Eli Lilly & Company (US), Bristol-Myers Squibb (US), Biogen Inc. (US).

Many of the major companies are focusing on introduction of new biologic drugs and advancement in the treatment of the diseases by minimizing the side effects of the drugs.

Unilife Corporation is a U.S. based developer, manufacturer and supplier of injectable drug delivery services. Precision-Therapy, Flex-Therapy, Imperium are the widely used injectors of this company.

Sanofi is a French multinational pharmaceutical company headquartered in France. This company has performing phase 3 trials on efpeglenatide and sotagliflozin for the treatment of diabetes and isatuximab for the treatment of Multiple Myeloma in 2017. ActHIB, DAPTACEL, Fluzone High-Dose and Imovax Rabies are some of the vaccines manufactured by this company.

Becton, Dickinson & Company a Germany headquartered company has introduced BD Neopak a prefillable glass syringe designed for high-volume injection of biologics.

Smiths Medicals an UK headquartered company is one of the leading pharmaceutical manufacturing and research company. Varivax SDV, Menactra VL, Adacel SYR and Decavac SYRG are some of the major vaccines of this company.

Eli Lilly & Company is a U.S. based pharmaceutical company. This company has recently got an approval for Olumiant for the treatment of Arthritics.

AstraZeneca an UK headquartered company has announced positive top-line results for its licensed asthma biologic benralizumab. Arimidex (anastrozole) and Casodex (bicalutamide) are some of the major drug by the company for the treatment of Cancer.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/biologics-market-1339